Specialty pharmaceutical company Endo International Plc has held discussions with private equity firms about potential asset sales as it seeks to reduce its more than $8 billion debt pile, according to people familiar with the matter.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
